Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
1.990
-0.010 (-0.50%)
At close: Oct 24, 2025, 4:00 PM EDT
1.980
-0.010 (-0.50%)
After-hours: Oct 24, 2025, 5:54 PM EDT
Opus Genetics Employees
Opus Genetics had 18 employees as of December 31, 2024. The number of employees increased by 4 or 28.57% compared to the previous year.
Employees
18
Change (1Y)
4
Growth (1Y)
28.57%
Revenue / Employee
$856,722
Profits / Employee
-$3,237,500
Market Cap
125.46M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18 | 4 | 28.57% |
| Dec 31, 2023 | 14 | 5 | 55.56% |
| Dec 31, 2022 | 9 | 1 | 12.50% |
| Dec 31, 2021 | 8 | 3 | 60.00% |
| Dec 31, 2020 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IRD News
- 11 days ago - Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference - GlobeNewsWire
- 23 days ago - Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025 - GlobeNewsWire
- 25 days ago - Opus Genetics, Inc. - Special Call - Seeking Alpha
- 25 days ago - Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) - GlobeNewsWire
- 6 weeks ago - Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions - GlobeNewsWire
- 7 weeks ago - Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 7 weeks ago - Opus Genetics Appoints Rob Gagnon as Chief Financial Officer - GlobeNewsWire